| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | White DE | |
| P433 | issue | 1 | |
| P921 | main subject | vitiligo | Q180152 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 81-84 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Journal of Immunotherapy with Emphasis on Tumor Immunology | Q27714027 |
| P1476 | title | Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy | |
| P478 | volume | 19 |
| Q39982281 | Anti-tumor immunity elicited by adenovirus encoding AdhTrp2 or AdmTrp2 without vitiligo |
| Q34276512 | Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". |
| Q37390912 | B16 as a mouse model for human melanoma |
| Q34703616 | Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer |
| Q38088635 | Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation |
| Q82853662 | Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses |
| Q35196765 | Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience |
| Q34487698 | Combination cancer immunotherapy and new immunomodulatory targets |
| Q36375152 | Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp |
| Q42011891 | Conceptual aspects of self and nonself discrimination |
| Q36375693 | Coupling and uncoupling of tumor immunity and autoimmunity |
| Q35190925 | Creating therapeutic cancer vaccines: notes from the battlefield |
| Q60958246 | Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer |
| Q36367821 | Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. |
| Q35946196 | Developing recombinant and synthetic vaccines for the treatment of melanoma. |
| Q34647354 | Development of effective immunotherapy for the treatment of patients with cancer |
| Q77317862 | Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response |
| Q36693023 | Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity |
| Q40434820 | Effects of dendritic cells from cord blood CD34+ cells on human hepatocarcinoma cell line BEL-7402 in vitro and in SCID mice |
| Q36369502 | Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy |
| Q37114367 | Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? |
| Q34335379 | Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial |
| Q28360452 | Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidity |
| Q35741270 | Fc receptors are required in passive and active immunity to melanoma |
| Q35948302 | Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. |
| Q42947076 | High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals |
| Q41533232 | Human Tumor Antigens and Cancer Immunotherapy |
| Q41687574 | Human tumor antigens recognized by T-cells |
| Q39880454 | IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells |
| Q36456744 | Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules |
| Q24647904 | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
| Q36713763 | Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction |
| Q39329603 | Immune and molecular correlates in melanoma treated with immune checkpoint blockade |
| Q33604121 | Immune-based therapeutics for pediatric cancer |
| Q33835011 | Immunologic functions as prognostic indicators in melanoma |
| Q36453216 | Immunotherapy for melanoma: current status and perspectives |
| Q36375982 | Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease |
| Q47287952 | Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry |
| Q35976297 | Inducing autoimmune disease to treat cancer |
| Q39896570 | Infection-mimicking materials to program dendritic cells in situ |
| Q30370026 | Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma. |
| Q37070898 | Influence of immunotherapy with autologous dendritic cells on innate and adaptive immune response in cancer. |
| Q37851050 | Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes |
| Q34720087 | Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis |
| Q73542697 | Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines |
| Q30412320 | MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. |
| Q35110750 | Malignant mucosal melanoma of the head and neck — a review |
| Q36368332 | Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. |
| Q37110386 | Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells |
| Q26850001 | Melanoma-associated leukoderma - immunology in black and white? |
| Q53493928 | Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells. |
| Q36262520 | Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo |
| Q35605318 | NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma |
| Q37275309 | Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma |
| Q35044333 | Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans |
| Q33929076 | Progress in cancer vaccines by enhanced self-presentation |
| Q34570245 | Progress in the development of immunotherapy for the treatment of patients with cancer |
| Q36484723 | Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma |
| Q36174230 | Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma |
| Q26748863 | Safety of targeting tumor endothelial cell antigens |
| Q34455397 | Science, medicine, and the future: Cellular immunotherapy for cancer |
| Q35020518 | Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa |
| Q34422330 | Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. |
| Q30435893 | Strategies and challenges in eliciting immunity to melanoma |
| Q34414412 | T cells take aim at cancer |
| Q34108113 | Targeting pediatric malignancies for T cell-mediated immune responses |
| Q35210456 | The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors |
| Q35946203 | The new vaccines: building viruses that elicit antitumor immunity. |
| Q34982772 | The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells. |
| Q37047969 | Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma |
| Q36916492 | Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer |
| Q35739956 | Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. |
| Q36371632 | Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. |
| Q35064131 | Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. |
Search more.